% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Adolph:291102,
      author       = {J. E. Adolph and G. Fleischhack and S. Tschirner and L.
                      Rink and C. Dittes and R. Mikasch and P. Dammann and M.
                      Mynarek and D. Obrecht-Sturm and S. Rutkowski and B. Bison
                      and M. Warmuth-Metz and T. Pietsch and S. Pfister$^*$ and K.
                      Pajtler$^*$ and T. Milde$^*$ and R.-D. Kortmann and S.
                      Dietzsch and B. Timmermann and S. Tippelt},
      collaboration = {G. G. HIT-Network},
      title        = {{R}adiotherapy for {R}ecurrent {M}edulloblastoma in
                      {C}hildren and {A}dolescents: {S}urvival after
                      {R}e-{I}rradiation and {F}irst-{T}ime {I}rradiation.},
      journal      = {Cancers},
      volume       = {16},
      number       = {11},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2024-01307},
      pages        = {1955},
      year         = {2024},
      abstract     = {Radiotherapy (RT) involving craniospinal irradiation (CSI)
                      is important in the initial treatment of medulloblastoma. At
                      recurrence, the re-irradiation options are limited and
                      associated with severe side-effects.For pre-irradiated
                      patients, patients with re-irradiation (RT2) were matched by
                      sex, histology, time to recurrence, disease status and
                      treatment at recurrence to patients without RT2.A total of
                      42 pre-irradiated patients with RT2 were matched to 42
                      pre-irradiated controls without RT2. RT2 improved the median
                      PFS [21.0 (CI: 15.7-28.7) vs. 12.0 (CI: 8.1-21.0) months]
                      and OS [31.5 (CI: 27.6-64.8) vs. 20.0 (CI: 14.0-36.7)
                      months]. Concerning long-term survival after ten years, RT2
                      only lead to small improvements in OS $[8\%$ (CI: 1.4-45.3)
                      vs. $0\%].$ RT2 improved survival most without
                      (re)-resection [PFS: 17.5 (CI: 9.7-41.5) vs. 8.0 (CI:
                      6.6-12.2)/OS: 31.5 (CI: 27.6-NA) vs. 13.3 (CI: 8.1-20.1)
                      months]. In the RT-naïve patients, CSI at recurrence
                      improved their median PFS [25.0 (CI: 16.8-60.6) vs. 6.6 (CI:
                      1.5-NA) months] and OS [40.2 (CI: 18.7-NA) vs. 12.4 (CI:
                      4.4-NA) months].RT2 could improve the median survival in a
                      matched cohort but offered little benefit regarding
                      long-term survival. In RT-naïve patients, CSI greatly
                      improved their median and long-term survival.},
      keywords     = {medulloblastoma (Other) / radiotherapy (Other) /
                      re-irradiation (Other) / recurrence (Other) / resection
                      (Other)},
      cin          = {B062 / B310 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)B310-20160331 /
                      I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38893076},
      pmc          = {pmc:PMC11171022},
      doi          = {10.3390/cancers16111955},
      url          = {https://inrepo02.dkfz.de/record/291102},
}